ARID1A is altered in 55.86% of endometrial endometrioid adenocarcinoma patients [2].

ARID1A is an inclusion eligibility criterion in 2 clinical trials for endometrial endometrioid adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain ARID1A status and endometrial endometrioid adenocarcinoma as inclusion criteria, 2 are phase 1 (1 open) [3].

CDK4 is altered in 1.99% of endometrial endometrioid adenocarcinoma patients [2].

CDK4 is an inclusion eligibility criterion in 1 clinical trial for endometrial endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and endometrial endometrioid adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDK6 is altered in 1.11% of endometrial endometrioid adenocarcinoma patients [2].

CDK6 is an inclusion eligibility criterion in 1 clinical trial for endometrial endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and endometrial endometrioid adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KDM6A is altered in 6.74% of endometrial endometrioid adenocarcinoma patients [2].

KDM6A is an inclusion eligibility criterion in 1 clinical trial for endometrial endometrioid adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains KDM6A status and endometrial endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

KMT2C is altered in 9.83% of endometrial endometrioid adenocarcinoma patients [2].

KMT2C is an inclusion eligibility criterion in 1 clinical trial for endometrial endometrioid adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains KMT2C status and endometrial endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

KMT2D is altered in 25.83% of endometrial endometrioid adenocarcinoma patients [2].

KMT2D is an inclusion eligibility criterion in 1 clinical trial for endometrial endometrioid adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains KMT2D status and endometrial endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SMARCA2 is altered in 2.5% of endometrial endometrioid adenocarcinoma patients [2].

SMARCA2 is an inclusion eligibility criterion in 1 clinical trial for endometrial endometrioid adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCA2 status and endometrial endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SMARCA4 is altered in 9.86% of endometrial endometrioid adenocarcinoma patients [2].

SMARCA4 is an inclusion eligibility criterion in 2 clinical trials for endometrial endometrioid adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain SMARCA4 status and endometrial endometrioid adenocarcinoma as inclusion criteria, 2 are phase 1 (1 open) [3].

SMARCB1 is altered in 2.04% of endometrial endometrioid adenocarcinoma patients [2].

SMARCB1 is an inclusion eligibility criterion in 1 clinical trial for endometrial endometrioid adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCB1 status and endometrial endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SS18 is altered in 0.95% of endometrial endometrioid adenocarcinoma patients [2].

SS18 is an inclusion eligibility criterion in 1 clinical trial for endometrial endometrioid adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains SS18 status and endometrial endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SSX1 is an inclusion eligibility criterion in 1 clinical trial for endometrial endometrioid adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains SSX1 status and endometrial endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SSX2 is an inclusion eligibility criterion in 1 clinical trial for endometrial endometrioid adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains SSX2 status and endometrial endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SSX2B is an inclusion eligibility criterion in 1 clinical trial for endometrial endometrioid adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains SSX2B status and endometrial endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SSX4 is an inclusion eligibility criterion in 1 clinical trial for endometrial endometrioid adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains SSX4 status and endometrial endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].